Bonduelle SCA

XI'AN, China, Sept. 2, 2025 /PRNewswire/ -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), a leading bio-ingredient solution provider in the natural, health and personal care industry, today announced a groundbreaking identification of a class of natural polyphenolic compounds from a tea-derived product via its AI-Powered new drug research and development (R&D) platform. Preliminary tests demonstrate that these compounds exhibit significant activity in weight management, with key efficacy indicators outperforming current mainstream weight-managing drugs, injecting new momentum into global R&D of weight-managing drugs.

With a worsening global obesity crisis, the weight-managing product market is experiencing robust growth. Data shows that the global weight-managing product market reached USD423.27 billion in 2024 and is projected to expand at a compound annual growth rate (CAGR) of 9.5% to USD601.26 billion by 2029¹. This market growth is primarily driven by the expanding obese population and rising awareness of healthy weight management.

BON's AI platform integrates massive datasets of natural compounds and biomedical knowledge, leveraging advanced algorithms and innovative models. Its high-efficiency data analysis and screening capabilities have significantly shortened the component screening cycle traditionally associated with drug R&D, enabling the successful identification of these compounds with weight-loss potential. Preliminary animal studies showed significant weight reduction at specific compound doses, with no obvious adverse effects observed. Currently, the Company has established a dedicated team to advance follow-up work, including research into the compounds' mechanisms of action, structural optimization, expanded animal trials, and preparation for clinical trials.

BON believes that the weight-managing product market represents a large-scale therapeutic area with substantial growth potential. If the Company successfully launches this new drug, it is well-positioned to capture a significant share of the global weight management therapeutics market - a development that would fundamentally and revolutionarily enhance the Company's investment value while delivering substantial returns to shareholders.

Meanwhile, this R&D breakthrough has enabled the Company to efficiently and accurately identify weight-managing active molecules from natural tea-derived products. It also provides preliminary validation of the feasibility of BON's AI-based new drug R&D platform, helping the Company establish a highly efficient, new R&D model. This will lay a solid foundation for the Company's AI-driven R&D business focused on natural compound-based new drugs, accelerate the development of its AI-powered innovative drug research initiatives, and continue to create greater value for shareholders.

References：

1. https://www.thebusinessresearchcompany.com/report/weight-management-global-market-report

About Bon Natural Life Limited ("BON")

BON is a Cayman Islands company engaged in the business of natural, health, and personal care industries. For more information, please visit the Company's website at http://www.bnlus.com.

For more information, please contact:

Cindy Liu | IR

Email: bonnatural@appchem.cn 

Safe Harbor Statement

This press release contains certain statements that may include "forward-looking statements." All statements other than statements of historical fact included herein are "forward-looking statements." These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

View original content:https://www.prnewswire.com/news-releases/bon-announces-identification-of-promising-weight-managing-compounds-from-tea-via-ai-powered-new-drug-rd-platform-302543536.html

SOURCE Bon Natural Life Limited

XI'AN, China, Aug. 5, 2025 /PRNewswire/ -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or "the Company"), a leading provider of bio-ingredient solutions for the natural health and personal care industries, today announced reciept of compliance notification from the Nasdaq Stock Market LLC.

As previously reported on a Form 6-K filed with the U.S. Securities and Exchange Commission on July 11, 2025, Bon Natural Life Limited ( "the Company") received notification from the Nasdaq Hearings Panel (the "Panel") that the Company had regained compliance with Listing Rule 5550(a)(2) (the "Bid Price Rule"). The Panel also advised the Company that it will be subject to a one-year Discretionary Panel Monitor.

On July 29, 2025, the Company received notification from The Nasdaq Stock Market LLC confirming the Panel's decision and stating that the matter is now closed.

About Bon Natural Life Limited ("BON")

BON is a Cayman Islands company engaged in the business of natural, health, and personal care industries. For more information, please visit http://www.bnlus.com.

For more information, please contact:

Cindy Liu | IR  

Email: bonnatural@appchem.cn 

Safe Harbor Statement

This press release contains certain statements that may include "forward-looking statements." All statements other than statements of historical fact included herein are "forward-looking statements." These forward-looking statements are often identified by the use of forward-looking terminology such as "believes,""expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov).  All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

View original content:https://www.prnewswire.com/news-releases/bon-announces-reciept-of-nasdaq-compliance-letter-302521595.html

SOURCE Bon Natural Life Limited